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Unfolded protein responseEBV-immortalized B-lymphoblastoid cell lines are used as models for cellular transformation and as antigen-
presenting cells in immunological assays. LCLs vary in surface markers and other phenotypic properties, but
it is not known how this heterogeneity relates to the EBV life cycle. To explore correlations, we examined 62
LCLs for cellular and viral phenotypes. LCLs generated from pediatric and adult donors could similarly be
categorized as either low in EBV copy number or ﬂuctuating within a high range. High-copy status
accompanied higher lytic viral gene expression and lower latent gene expression. Inhibiting lytic EBV
replication did not affect cellular phenotype or lytic switch protein expression, indicating that an LCL's lytic
permissivity was a stable property. Among the cellular genes overexpressed in permissive LCLs were
unfolded protein response genes and plasma cell markers. Among genes overexpressed in non-permissive
LCLs were transcription factors involved in maintaining B cell lineage, in particular EBF1. This study suggests
previously undetected mechanisms by which cellular pathways inﬂuence the lytic reactivation of EBV.ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Epstein–Barr virus is a human gammaherpesvirus that infects
epithelial cells and B cells, and is distinguished from other
herpesviruses by its ability to induce proliferation and expansion
of B cells. In vivo EBV can cause mononucleosis during primary
infection, characterized by massive proliferation of lymphocytes
which then leads to viral persistence in the B lymphocytes
throughout one's lifetime. EBV persistence has been associated
with tumors including Burkitt's lymphoma and Hodgkin's disease,
and less conclusively with autoimmune diseases, particularly SLE.
Like most human herpesviruses EBV can induce complications in
immunosuppressed people, after primary infection or during
reactivation from latency; unlike most other herpesviruses (the
exception: HHV-8), EBV has the unusual ability to cause tumors in
these patients (Jenkins et al., 2003). Upon infection of a B cell, EBV
expresses six Epstein–Barr nuclear antigens (EBNAs) and two latent
membrane proteins (LMPs); this is known as the Latency III proﬁle.B cell proliferation requires functions encoded in most of the EBNAs
and contributions from LMP1 and LMP2A proteins that mimic CD40
and B cell receptor signaling respectively (Rickinson and Kieff,
2007). In vivo Latency III-transformed cells are quickly recognized
and killed off by cytotoxic T cells, although a minority of infected
cells survive, escaping detection by switching from Latency III to
more limited Latency I or II proﬁles of viral gene expression.
Without effective immune surveillance, Latency III-transformed B
cells can proliferate, and in immunosuppressed transplant recipients
this can lead to post-transplant lymphoproliferative disorder (PTLD)
(Dolcetti, 2007).
In vitro EBV infection is a convenient way to produce B-
lymphoblastoid cell lines (LCLs), which can be used as targets for
assays of cytotoxic T cells, as models for immortalization and
senescence, or as sources of patient-speciﬁc cells for genotyping.
LCLs are often used as models for PTLD (Markasz et al., 2006), as they
have similar morphology and phenotype involving high expression of
activation and adhesion markers, and grow readily in SCID/hu mice.
LCLs have been characterized for properties such as time to clonality,
rate of episome multiplication early in proliferation, frequency of Ig
isotypes, and the mutations and selection that eventually lead to truly
tumorigenic cell lines (Ryan et al., 2006; Sugden et al., 1979; Sugimoto
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CD38− CD23+ PTLDs derived from germinal center-experienced
“bystander” B cells than the CD38+ CD23− PTLDs that originate
from centroblasts (Rochford et al., 1993). LCLs are phenotypically
more heterogeneous than most studies presume, though they are
frequently treated as interchangeable. One study disagreed with the
consensus (CD10− CD19+ CD20+ CD21+ CD23+ CD30+ CD40+
CD40L− CD77− Fas+ OX40− OX40L−, IL-6 secreting) proﬁle of LCLs
(Durandy et al., 1997; Gregory et al., 1991; Shinozaki et al., 2001) by
describing a CD19−CD20− subgroup, which also produced less
soluble Ig and negligible amounts of the paracrine growth factors
IL-6 and IL-10 (Wroblewski et al., 2002). LCLs vary signiﬁcantly in
surface expression of CD38 and other markers (Dolcetti et al., 1999;
Khanolkar et al., 2003; Subklewe et al., 2005), and the nature of their
malignant mutations (Takahashi et al., 2003). These earlier ﬁndings
may suggest that LCLs should not be used interchangeably in clinical
studies.
Lytic reactivation is generally induced in vitro by the addition of
histone deacetylase (HDAC) inhibitors, which enhance acetylation of
the histones associated with the EBV episome, decondensing its
chromatin structure and remodeling the promoters for the Z and R
genes that encode the lytic switch proteins BZLF1/ZEBRA and BRLF1/
Rta (Countryman et al., 2008). These proteins are uniquely necessary
to induce the cascade of lytic EBV replication, which involves the
production of early viral proteins, followed by replication of viral DNA
by viral DNA polymerase, and production of late viral proteins
including the structural proteins that make up the viral particle.
Several human transcription factors are known to inﬂuence activation
of the Z promoter; two recent studies (Bhende et al., 2007; Sun and
Thorley-Lawson, 2007) added to this list XBP-1, a protein that induces
B cells to exit either a proliferating or quiescent phenotype and
terminally differentiate into antibody-secreting plasma cells (PCs).
XBP-1-mediated induction of ZEBRA expression conﬁrms a series of
associations between B cell terminal differentiation and lytic
reactivation which began with the ﬁndings of Wendel-Hansen et al.
(1987) that in a given LCL, a non-proliferating minority of cells
contain high levels of cytoplasmic Ig and low levels of latent EBV
antigens. This ﬁnding also ﬁts into a model for in vivo virus
propagation over decades. In this model, latent virus is maintained
in quiescent memory cells in the blood that, when they become
activated, trafﬁc to the secondary lymphoid organs and differentiate
into PCs. Concomitantly, they activate the lytic program and make
virus particles, leading to the infection of bystander B cells in those
organs (Thorley-Lawson and Gross, 2004).
Gene expression proﬁling has been used in vitro to investigate
the effects of EBV infection on both epithelial cells and B
lymphocytes. Studies have looked at genes inﬂuenced by Latency
III infection, Latency I infection, expression of isolated EBV proteins
(LMP1, LMP2A), infections using knockout strains of virus lacking
EBNA2 or EBNA3B/3C, and the effects of inducing EBV lytic
replication in Latency I-type cells (Cahir-McFarland et al., 2004;
Carter et al., 2002; Chen et al., 2006; Morris et al., 2008; Portis and
Longnecker, 2003; Spender et al., 2006; Yuan et al., 2006; Zhao
et al., 2006). Microarrays have been used clinically for many
diseases including multiple myeloma, Hodgkin's disease, PTLD, NPC,
and SLE to search for gene expression proﬁles that correlate with
acute and/or EBV-positive cases. In this study we characterized how
LCLs' properties correlated in their permissivity for lytic reactiva-
tion. We tested the hypotheses that LCLs which differentiate toward
a PC phenotype become permissive for EBV reactivation, and that
cell lines with fewer PC-like properties will experience less EBV
reactivation. Representative permissive and non-permissive LCLs
were examined by microarray gene expression proﬁling, and
conﬁrmed with quantitative real-time RT-PCR, to identify several
genes whose expression levels were associated with higher or lower
levels of lytic permissivity.Results
Levels of EBV DNA/cell correlate with spontaneous lytic reactivation
within a characteristic range in both adult- and juvenile-derived LCLs
We hypothesized that LCLs vary in permissivity for EBV reactiva-
tion in a manner inﬂuenced by the ontology of the cells that gave rise
to the LCL. We measured the EBV DNA content in 62 independently
established LCLs which could be divided into two groups (adult or
pediatric) depending on the age of the B cell donor. In both groups the
majority of cell lines had b200 copies of EBV DNA/cell with some
ranging above 500 copies/cell, when measured at a single time point
(Fig. 1) LCLs derived from healthy adult donors had a mean value of
254.4 (95% CI 151.7–357.2) and a median value of 124.0. LCLs derived
from the peripheral B cells of pediatric transplant candidates had a
mean of 193.4 copies of EBV DNA/cell (95% CI 132.6–254.2) and a
median value of 123.8. LCLs from adult and pediatric donors were not
statistically different in EBV DNA content, either in this cross-
sectional measurement or in longitudinal observations (not shown).
Indeed, we found no signiﬁcant differences regardless of how the LCLs
were stratiﬁed (age, gender or, for adults, HIV status). Of the 62 cell
lines, 24 (38%) had N200 copies of EBV DNA/cell and, upon further
analysis, were eventually classiﬁed as permissive for spontaneous
EBV lytic reactivation.
Permissive and non-permissive LCLs were also subcloned at
limiting dilutions and measured for EBV DNA/cell to conﬁrm that
their lytic permissivity phenotype was shared by the daughter cell
lines (Fig 1C). In addition to resembling their parent lines in
morphology and growth rate, all sublines from the low-copy lines
were low-copy like the parent, and only three of 22 sublines from one
of the high-copy lines were measured as low-copy. That subcloning
did not affect the phenotype was expected since all our LCLs had been
growing in culture for at least 3 months prior to use in these
experiments. This is in agreement with the study of Ryan et al. (2006)
showing that LCLs reach clonality or stable biclonality within 2
months of establishment. However, as our aim was to characterize a
set of LCLs that were representative of those widely used in clinical
and scientiﬁc assays, our cell lines were not all subclones. Typically,
LCLs are not normally subcloned or investigated for clonality before
being used in the laboratory.
It has been previously shown that within 2 months post-infection
the number of latent EBV episomes per cell in LCLs commonly
increases from 1 or 2 per cell to dozens through mechanisms not
related to classical episome maintenance (replication once per cell
cycle in S phase from oriP) (Kieff and Rickinson, 2007). Since most
LCLs undergo some level of spontaneous lytic reactivation, and this
lytic permissivity varies among LCLs (Adhikary et al., 2007; Keating
et al., 2002), when LCLs are used in therapeutic protocols they are
routinely cultured in the presence of acyclovir (a nucleoside analogue
that inhibits herpesviral DNA polymerase and prevents lytic, but not
latent, viral replication) to suppress the production of infectious virus
(Bollard et al., 2004). To investigate whether the high levels of EBV
DNA in some LCLs were the consequence of lytic reactivation, we grew
LCLs in the presence of acyclovir (ACV). When grown with ACV, all
LCLs had their levels of EBV DNA/cell reduced below 100 (data from
four representative LCLs shown in Fig. 2A). Thus, for LCLs maintained
without lytic inducers or lytic-inhibiting drugs, the amount of EBV
DNA/cell is a marker for lytic permissivity of the population. As LCLs
grow in culture and undergo spontaneous lytic replication, a typical
LCL might be expected to gradually increase its number of episomes/
cell as a result of re-infection by virus in the supernatant.
Alternatively, as the cells in each line that are disposed to enter a
lytic replication cycle reactivate and die off, the cell line might
decrease over time in its lytic permissivity. Neither trend was
observed (Fig. 2). When grown without ACV, each LCL with greater
than a baseline level of lytic permissivity showed levels of EBV DNA/
Fig. 1. Sets of proliferating LCLs from pediatric and adult donors have comparable levels
of EBV DNA content. LCLs generated from pediatric transplant candidates (n=32) and
fromhealthy adults (n=30)weremaintained forN2months andmeasured for EBVDNA
content 2 days after being split to equal densities. (A) In each group, the majority of cell
lines had b200 copies of EBV DNA/cell, while some ranged above 500 copies/cell. (B)
Boxes show the 25th and 75th percentiles; diamonds represent values outside 1.5× the
interquartile range. (C) Four LCLswere subcloned, with subclones allowed to diverge for
6 weeks before beingmeasured for EBV DNA/cell. White diamonds represent subclones
(mean of 2 time points), while black diamonds represent parent lines (mean of 7 time
points). Bars indicate geometric means of subclones (n=18–22) for each LCL.
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These transient increases and decreases did not correlate with the
days on which cultures were passaged, or with the density of cells in
the media. Although the level of EBV DNA/cell in each LCL ﬂuctuated
from day to day, there was no steady trend upward or downward over
time.Cell lines with consistently high levels of EBV reactivation (so-
called permissive LCLs) might be engaged in a self-reinforcing
reactivation cycle that could be broken by the addition of acyclovir.
To test this, we cultured permissive and non-permissive LCLs for
14 days in ACV and then removed it and continued culture
passage. Non-permissive LCLs, represented by LCL21 (Fig. 2B),
maintained the low-copy phenotype before, during and after the
application of ACV. Permissive LCLs, represented by LCL23 (Fig. 2C),
had their EBV DNA/cell reduced to baseline level when grown in
ACV, but immediately after the removal of ACV returned to their
high-copy phenotype. This suggests that the rate at which spon-
taneous EBV lytic reactivation takes place in an LCL is inﬂuenced
not by the number of viral episomes or by ongoing virus pro-
duction, but by cellular factors whose expression is a characteristic
of that cell line.
All LCLs show a Latency III pattern of gene expression with a detectable
level of lytic reactivation
To characterize LCLs for their lytic permissivity, and to conﬁrm
that they had comparable Latency III proﬁles of viral gene
expression, we quantiﬁed 15 viral lytic and latent mRNA
transcripts using real-time RT-PCR. For a subset of LCLs (n≥21),
we measured the level of EBV DNA/cell for 5 days, with RNA
extracted on the third day. Every LCL expressed transcripts for the
full complement of EBV Latency III genes (Fig. 3). Every LCL also
expressed detectable levels of the transcripts for three early lytic
genes (BZLF1, which produces the lytic switch protein ZEBRA;
BMLF1, which produces the abundant nuclear EB2 protein; and the
lytic F promoter, which represented the majority of transcripts
detected using primers speciﬁc for sequences in the downstream Q
region). The expression of these lytic mRNAs correlated positively
with the number of EBV genomes in an LCL (Fig. 3B–D). Signiﬁcant
linear correlations were also found between the number of EBV
genomes/cell and the percentage of cells expressing early (ZEBRA)
or late (gB/gp110) lytic viral proteins as detected by ﬂow
cytometry (Supplementary Fig. 1). These data show that in lytically
permissive LCLs the entire process of lytic reactivation is occurring,
rather than an abortive expression of early lytic proteins and EBV
DNA replication.
The expression of latent EBV genes in an LCL correlates negatively
(but weakly) with its permissivity for lytic reactivation
We also measured the relative expression levels of all six EBNA
genes and two LMP genes in the same subset of LCLs (n≥21). All eight
were expressed in every LCL; themost abundant transcript was LMP1,
and the least abundant was EBNA3A (Fig. 3A). Fig. 4 shows the level of
mRNA for each latent gene plotted against the level of EBV DNA/cell.
For EBNA1, -2, -3A, -3B, -3C, -LP, LMP1, and LMP2B, the relationship is
similar and slightly negative, non-linear, and attributable to a
minority of non-permissive LCLs that contain high levels of the
transcript in question. Only EBNA3A (Fig. 4D) and EBNA3C (Fig. 4F)
generated a signiﬁcant negative linear regression (pb0.05) between
gene expression levels and EBV DNA/cell.
The only latent gene product whose expression positively
correlated with the level of lytic EBV DNA/cell was LMP2A (Fig. 4H).
This relationship is not as strong as the correlation between EBV DNA
content and BZLF1 and BMLF1 gene expression, and it resembles the
relationship between EBV DNA content and the other latent genes, in
that non-permissive LCLs show a wider range of gene expression
levels than permissive LCLs. No inverse relationship was detected
between LMP1 and LMP2A expression, even though LMP1 is known to
repress lytic reactivation in its role as a CD40 mimic (Adler et al.,
2002), while LMP2A signaling can downregulate the expression of
LMP1 (Stewart et al., 2004).
Fig. 2. In some LCLs, EBV DNA/cell ﬂuctuates within a certain range and is reduced to a baseline level by the antiviral drug acyclovir. (A) Four LCLs were grown in complete media and
passed regularly to equal densities. The number of EBV genomes/cell in each LCL did not remain stable or steadily increase over time. In the presence of acyclovir EBV DNA/cell
reached a stably low level, with no effect on cellular morphology. Non-permissive LCL21 (B) and highly permissive LCL23 (C) were grown inmedia without ACV from days 0 to 20. On
day 4, each LCL was split into two ﬂasks, with or without ACV. On day 14, each LCL growing under ACV was split into two ﬂasks, with or without ACV. Upon removal of ACV, LCL23
returned to its high-copy phenotype.
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After months in culture LCLs are expected to have completed the
shift from using the W promoter (Wp) to using the C promoter (Cp)
for expressing EBNA genes. RT-PCR primers were designed to detect
the 5′ ends of polycistronic EBNA transcripts and amplify RNAs with
C2 toW1 splices (representing transcription from the Cp), orW0 toW1Fig. 3. Viral gene expression in LCLs. Cell lines (n≥21) were measured for EBV DNA and RN
real-time RT-PCR. Each of nine latent transcripts and three lytic transcripts was detectable in
DNA content. Levels of EBV DNA/cell (mean of 5 time points) were plotted against levels
representing the lytic transcripts BZLF1/ZEBRA (B); BMLF1/EB2 (C); and F promoter (D).
variation adjusted for sample size.splices (representing transcription from the Wp). Importantly,
alternative splices between these exons determine whether the
mRNA contains an EBNA-LP start codon (LP+) or no EBNA-LP start
codon (LP−) Therefore, two sets of 5′ primers were used to
distinguish LP+ from LP− transcripts (Supplementary Table 1).
EBNA-LP expression level was estimated by adding together the
detected levels of C2:W1 and W0:W1 LP+ splices. LP− splices wereA content after growing for N3 months. (A) Levels of mRNA/cell were measured using
every LCL measured. (B–D) Permissivity for EBV lytic reactivation correlates with EBV
of EBV mRNA (1 time point, taken 2 days after cells were split to a common density)
Statistics shown are the p-value derived from Student's t test, and the coefﬁcient of
Fig. 4. No strong correlation exists between EBV latent gene expression and EBV DNA content. LCLs (n≥17) were measured for EBV DNA and RNA content after growing for N3
months, as described in Fig. 3. Gene expression wasmeasured for EBV nuclear antigens 1 (A), 2 (B), leader protein (C), 3A (D), 3B (E), and 3C (F), and EBV latent membrane proteins 1
(G), 2A (H) and 2B (I). Statistics shown are as in Fig. 3. Linear regressions are shown when p≤0.05.
Fig. 5. Both W and C promoters are actively making EBNA transcripts in all LCLs. LCLs
(n=22) were measured for EBV DNA and RNA content after growing for N3 months, as
described in Fig. 3. We detected polycistronic EBNA transcripts representing four splice
variants—either C2:W1 or W0:W1, and either containing or not containing an EBNA-LP
start codon. Each LCL contained all four splice variants. Non-permissive LCLs (b200 EBV
genomes/cell) contained more transcripts of each splice variant, as with all other latent
transcripts except LMP2A (Figs. 3–4).
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EBNA-LP. As predicted, the RNA levels for the 5′ ends of EBNA
transcripts (sum of the Cp and Wp cDNAs) were similar to the RNA
levels for the 3′ ends of EBNA transcripts (sum of the EBNA ORF
cDNAs). This concordance suggested that the efﬁciency of the reverse
transcription did not grossly favor some transcripts over others.
Although C transcripts were more abundant than W transcripts, all
four targets were detected in every LCL (Fig. 5). There was no
correlation between time in culture and having a greater ratio of C
promoter to W promoter activity (data not shown). W and C
promoters appear to share the property of being more highly
expressed in non-permissive LCLs, and this relationship reaches
statistical signiﬁcance for two of four transcripts (Fig. 5). In agreement
with recent ﬁndings (Elliott et al., 2004), our data indicate that theWp
is never totally silenced even after more than 6 months in culture.
Inhibition of lytic replication does not affect the rate of spontaneous
BZLF1 induction
Varying levels of lytic replication in LCLs might not be directly
related to the levels of ZEBRA induction, but instead correlate more
closely with the level of success in translating that initial lytic switch
into full-ﬂedged viral replication accompanied by production of late
lytic proteins. To characterize spontaneous reactivation at the level of
individual cells rather than in pooled populations, we used ﬂow
cytometry to detect the number of cells in each cell line expressinglytic virus proteins, and the level of expression of these proteins, when
grown with or without acyclovir. Just as with lytic mRNA expression,
there was a linear relationship between the number of EBV lytic
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(ZEBRA) and late (gp110) lytic proteins (Supplementary Fig. 1). The
reactivating cells in non-permissive LCL38, though less numerous
than those in permissive LCL01, stain just as brightly for ZEBRA and
gp110, indicating that although LCLs vary in the fraction of cells that
switch into lytic reactivation, the cells that do so produce similar
levels of lytic proteins (Fig. 6). The ratio of double-positive (ZEBRA+
gp110+) cells to single-positive (ZEBRA+) cells was consistently
between 10% and 30% in both permissive and non-permissive LCLs,
indicating that although LCLs vary in permissivity for ZEBRA
induction, they are similar in their ability to undergo the full cycle
of lytic replication once ZEBRA is induced.
Permissive LCLs, maintained in the presence of ACV for 4 weeks,
were compared with the same LCLs grown with no antiviral drugs.
ACV greatly reduced the production of gp110, but had no effect on
either the number of cells producing ZEBRA or the level of ZEBRA
produced in those cells (Fig. 6A). Flow cytometry analysis for two
permissive LCLs grown with or without ACV at four time points found
that ACV did not affect the number of cells producing ZEBRA (Fig. 6C),
but did reduce the number of ZEBRA+ gp110+ double-positive cells,
expressed both as a percent of the total cell population (Fig. 6D) and
as a percent of the ZEBRA+ cells (Fig. 6E). This further suggests that
the “high-copy” status of an LCL is a stable phenotype characterized by
greater permissivity for BZLF1 activation, and is independent of
whether lytic replication of the genome actually occurs.
Proﬁling LCLs by their display of surface markers
We hypothesized that high rates of lytic permissivity might be
associated with LCLs of a non-memory cell lineage, or with those that
experience more spontaneous differentiation toward PC status. Also,
LCLs with reduced lytic reactivation might have lost certain aspects ofFig. 6. Permissive LCLs contain more cells expressing lytic EBV proteins. (A, B) Permissive
protein ZEBRA(Z) and the late viral protein gB/gp110. In cells grown without acyclovir,
representative of 9 LCLs at 4 time points. (C, D, E) Quantiﬁcation of ﬂow scatterplots. Two per
expression. (C) The ratio of ZEBRA-positive cells to total cells at each time point. (D) The ra
positive cells to ZEBRA-positive cells. Even long-term treatment with ACV only reduces the nthe B cell phenotype, such as surface immunoglobulin expression.
Panels of ﬂuorescently labeled antibodies were used to characterize
the LCLs for numerous cell surface markers, including CD138/
Syndecan1 and CD38 (plasma cells); CD27 (memory and plasma
cells); B220 (naive cells); CD23 and CD69 (activated B cells); CD30
(activated B cells and some tumors); HLA class I and class II; pan-B cell
markers CD20, BAFFR/BR3, and CD45; CD40 (a pan-B cell marker and
signaling molecule mimicked by LMP1); CD19 (pan-B cell marker and
part of the B cell receptor complex); isotypes IgM, IgD, IgG and IgA;
and a reagent that stains all human antibodies (goat pan-Ig). Nineteen
LCLs were maintained without ACV and measured for all of these
markers.
Although there were examples of LCLs having low levels of one
surfacemarker or another (CD19, CD40, CD45, HLA II), and they varied
in intensity of CD38, CD27, and CD138, there was no coherent
phenotypic pattern (e.g. enhanced PC differentiation) that could be
associated with EBV reactivation. Linear regression of each surface
marker suggested a negative correlation between EBV DNA content
and the percent of cells positive for CD45 (p=0.006, R2adj=33.3%),
CD38 (p=0.020, R2adj=23.5%), and CD40 (p=0.031, R2adj=
20.0%), and a positive correlation between EBV DNA content and
the percent of cells positive for B220 (p=0.017, R2adj=25.0%).
When we used mean ﬂuorescence intensity of the cells, rather than
percent positive, as the metric, the only correlation suggested by
linear regression was a positive one between B220 and EBV DNA
content (p=0.035, R2adj=19.0%). Table 1 shows that there was no
association between EBV DNA content and class-switched or IgM+
IgD+ status, and no consistent correlations with other phenotypic
markers. For eight cell lines examinedwith andwithout ACV, the drug
had no effect on surfacemarker expression, conﬁrming that long-term
inhibition of EBV lytic replication did not impact a cell line's surface
marker phenotype (data not shown).LCL01 and non-permissive LCL38 were stained for expression of the immediate early
the proportion of cells expressing Z and/or gB is greater in 01 than in 38. Data are
missive LCLs, grownwith or without ACV, were stained on 4 days each for ZEBRA and gB
tio of ZEBRA/gB-double-positive cells to total cells. (E) The ratio of ZEBRA/gB-double-
umber of cells expressing late lytic genes—not the % of cells initiating lytic reactivation.
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LCLs by microarray
From the HapMap project it is clear that LCLs differ in their
expression of a wide range of cellular proteins, as a result of
polymorphisms (Zhang et al., 2008), so we used LCLs as a system to
detect connections between cellular gene expression and EBV
activity in latently infected cells. We selected two permissive LCLs
(LCL33 and LCL77) and two non-permissive LCLs (LCL21 and LCL38),
maintained them in separate ACV+ and ACV− conditions for 2
months, and isolated DNA and RNA 2 days after passage at the same
density. cDNA was hybridized to Illumina HumanRef-8 v2 BeadChips
containing probes for 20589 human mRNA sequences. For every
probe, we ﬁrst compared the average intensity of the 4 LCLs grown
with ACV with the average intensity of the 4 LCLs grown without ACV
(Fig. 7A), and found no signiﬁcant effects on any cellular genes. We
then compared the average intensity of the permissive samples
(LCL33 ACV+ and ACV−, LCL77 ACV+ and ACV−) with the average
intensity of the non-permissive samples (LCL21 ACV+ and ACV−,
LCL38 ACV+ and ACV−), and found a much greater degree of
variation (Fig. 7B), although the R2 value of 0.993 indicates how
similar the phenotypes of the cells in this study are.
We used efﬁciency analysis of several transformations of the data
to identify the process that would generate the most repeatable list of
genes with signiﬁcant absolute differences in expression between
permissive and non-permissive LCLs. Online caGEDA software
indicated that the most consistent determination of signiﬁcance
came from data that were untransformed and had been deﬁned as
signiﬁcant using the J5 formula. By this measure, the most repeatable
threshold for signiﬁcance was J5=32.5, and 34 transcripts were
found to be above this threshold—20 overexpressed in permissive
LCLs, and 14 overexpressed in non-permissive LCLs (Fig. 7C).
Supplementary Tables 2 and 3 list all the transcripts whose over-
expression in either non-permissive (Table S2) or permissive (Table
S3) LCLs led to a J5 score above 10.0. We also quantiﬁed the difference
between permissive and non-permissive LCLs by measuring the fold
difference, or ratio between the averages of the groups. Supplemen-
tary Tables 4 and 5 describe the transcripts that were overexpressed
by a fold difference above 1.75 in either non-permissive (Table S4) or
permissive (Table S5) LCLs.
Differentially expressed sets of genes in permissive andnon-permissive LCLs
In light of the small sample size usedwith this microarray, we used
statistical analysis software not just to identify individual genes, but
also to seek out patterns of overexpression in entire groups of genes
associated with pathways, biological processes, or the curated results
of other microarray studies. GSEA (Gene Set Enrichment Analysis)
was used to analyze the results as a whole, ranking all genes by
signiﬁcance of their difference between the two groups of LCLs, and
then identifying gene sets that were overrepresented at either
extreme of the ranking (Subramanian et al., 2005). Curated gene
sets associated with non-permissive LCLs included genes under-
expressed in AIDS-associated primary effusion lymphoma (Klein et al.,
2003); downregulated by p21 and p53 (Wu et al., 2002); over-
expressed in CD10+ hematopoietic progenitor cells with B cell
potential (Haddad et al., 2004); and upregulated in multiple myeloma
cell lines after activation by N-ras or IL-6 (Croonquist et al., 2003).
Curated gene sets associated with permissive LCLs included genes
upregulated by p53, IFN-α or IFN-γ (Browne et al., 2001; Inga et al.,
2002; Sana et al., 2005); overexpressed in all types of plasma cells in
vivo (Tarte et al., 2003); overexpressed in peripheral blood B cells of
lupus patients (Bennett et al., 2003); and associated with the ART
vesicular trafﬁcking pathway.
Motif-based gene sets associated with non-permissive LCLs
included those with promoter sequences predicted to be activated
60 M.L. Davies et al. / Virology 400 (2010) 53–67or repressed by transcription factors PAX8, PAX6, NF-IL3, FOXO1,
EGR1/2/3, E2F1, CUTL1/CDP, and several microRNAs including the
oncogenic miR-155, -221, and -222, and the anti-inﬂammatory miR-
346 (Alsaleh et al., 2009; Lambeth et al., 2009; Teng and
Papavasiliou, 2009). Motif-based gene sets associated with permis-
sive LCLs were those with motifs for ATF-6, XBP-1, HTF-1, and
STAT5A, and microRNAs miR-338 and miR-518A/E/F. Although
dozens of both motif-based and curated gene sets were enriched at
a false discovery rate (FDR) b0.25 in non-permissive LCLs, only seven
motif-based gene sets were enriched at FDR b0.50 in permissive
LCLs. The most enriched gene sets detected by GSEA are described in
Supplementary Table 6.
DAVID, employing a canonical database of gene ontologies and
other groups of genes such as KEGG pathways (Huang et al., 2009),Fig. 7. Genes differentially expressed between permissive and non-permissive LCLs. (A) F
maintained without acyclovir. No genes show signiﬁcant differential expression between th
were compared with 2 non-permissive LCLs grown with and without ACV. Red points re
quantiﬁed for each gene using the J5 formula, and efﬁciency analysis predicted that themost
33 genes had signiﬁcance above 32.50.was used to analyze lists of genes signiﬁcantly overexpressed in
permissive or non-permissive LCLs and identify gene ontologies
that contained signiﬁcant genes. We used four different deﬁnitions
of signiﬁcance (J5N10.0; J5N7.0; fold difference N1.75; fold
difference N1.5) to create these lists, to see whether the genes
identiﬁed by one method would also be identiﬁed by others. All
gene ontologies that contained at least one signiﬁcant gene, and
were associated with immunology or transcription factor activity,
were collected. Similar ontologies (e.g. “transcription”, “transcription
factor activity”, and “regulation of transcription”) were combined,
and all such ontologies are listed in Supplementary Table 7. The
small number of differentially expressed genes identiﬁed from these
categories is expected from a comparison of cells with such similar
phenotypes.or all genes, 4 LCLs maintained with acyclovir were compared with the same 4 LCLs
e two populations. (B) For all genes, 2 permissive LCLs, grown with and without ACV,
present genes with J5N32.50. (C) The absolute difference between populations was
repeatable threshold for signiﬁcancewas J5=32.50. Thirty four transcripts representing
Table 2
Genes found by RT-PCR to be most differentially expressed between permissive and
non-permissive LCLs.
pa Fold change
pb .05 (non-permissive vs. permissive)
CD40 b0.001 1.76
EVL 0.001 1.84
LRMP (Jaw-1) 0.005 1.98
ETS1 0.006 1.38
CD79B 0.009 1.54
TNFSF13B (BAFF) 0.011 1.68
CD99 0.021 1.38
PAX5 (BSAP) 0.026 1.42
ITGB (Integrin β2) 0.035 1.47
RAC2 0.035 1.23
TCF3 (E2A) 0.039 1.31
NFATC1 0.048 1.67
Fold differenceN2.0 (non-permissive/permissive)
IFI27 0.191 15.46
EGR1 (Zif-268) 0.075 3.98
CD38 0.114 3.38
KLF2 0.077 2.11
CCR7 (EBI1) 0.057 2.10
GNA15 (G α15) 0.076 2.09
Both
EBF1 0.002 3.25
PTPRK 0.005 3.42
ID2 0.005 4.23
TSC22D3 (GILZ) 0.014 2.20
CD69 0.031 2.63
EBI2 0.038 2.03
pb0.05 (permissive vs. non-permissive)
DNAJB11 0.012 1.59
CCR10 0.015 1.49
SDF2L1 0.016 1.77
CALR 0.018 1.52
ARMET 0.045 1.49
Fold differenceN2.0 (permissive/non-permissive)
LEPREL1 0.067 4.53
SDC1 (Syndecan) 0.101 2.85
RAB31 (Rab22b) 0.155 2.11
CD27 0.086 2.02
Both
HSP90B1 (Grp94) 0.009 2.16
n=7 in each population.
a From a 2-sample t test.
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To further explore hypotheses suggested by themicroarray results,
we subjected a larger group of LCLs (seven permissive and seven non-
permissive) to an RT-PCR based assay for cellular gene expression.We
investigated 92 genes, which were identiﬁed by strongly differential
expression in the microarray, by relevance to B cell or EBV biology, or
both. Seven of the selected genes (BCL11A, BCL6, CD40LG, CT45-4, HLA-
DRB3, HLA-DRB5, U2B7) were not detected in the majority of samples.
For the remaining 85 genes, we used the 2−ΔΔCt method to quantify
relative gene expression, normalizing the results to an endogenous
control and then comparing that value to the value for a reference
sample, LCL17. Each measurement was normalized twice, with either
GAPDH or B2M as the endogenous control gene, and these two
normalized values were averaged together. The mean for seven
permissive LCLs (mean EBV DNA/cell 42.9, SD 23.6) was compared
with the mean for seven non-permissive LCLs (mean EBV DNA/cell
1029.1, SD 520.6), and all 85 genes (plus two more endogenous
controls, HPRT1 and ACTB) were characterized for signiﬁcance of the
difference between permissive and non-permissive LCLs. All cellular
genesmeasured by RT-PCR are listed in Supplementary Tables 8 and 9,
ranked both by p-value of the difference derived from a two-sample t
test (Table S8) and by relative fold difference between the two
populations of LCLs (Table S9).
Table 2 shows all the genes whose differential expression was
signiﬁcant at a level of pb0.05, or a fold difference greater than twofold.
Although the three PC-associated transcription factors investigated
(XBP1; IRF4/MUM1; PRDM1/Blimp-1) were not overexpressed in
permissive LCLs, we did detect a difference in expression of SDC1,
encoding the plasma cell surface marker Syndecan-1/CD138; and
CCR10, encodinga chemokine receptor (theCCL27/CCL28 receptor) that
is upregulated on PCs and EBV-immortalized B cell lines, but not EBV+
Burkitt's lymphoma lines (Nakayama et al., 2002, 2003). The difference
in CCR10 expression was small but consistent, while the high fold
difference in SDC1 expressionwas the result of twodata points (Fig. 8B).
Interestingly, although permissive LCLs did not show transcription
factor expression indicative of increased plasma cell differentiation,
non-permissive LCLs overexpressed EBF1, PAX5, TCF3/E2A, and ETS1,
which are all components of a transcription factor network that
maintains the proliferating B cell phenotype and inhibits the XBP-1/
Blimp-1 network (Fig. 8C). The three genesmost overexpressed in non-
permissive LCLs were EBF1, ID2, and PTPRK. ID2 encodes a non-DNA-
binding transcription factor thought to inhibit Pax-5 activity and in turn
be downregulated by EBF-1 and Pax-5 (Thal et al., 2009).PTPRK encodes
a receptor tyrosine phosphatase that regulates activity of proteins
including Src and EGFR, and mediates anti-proliferative and pro-
migratory effects of TGF-β (Wang et al., 2005; Xu et al., 2005). Table 2
shows that these were the only genes that were both overexpressed as
determined by signiﬁcance of pb0.01, and overexpressed by fold
difference greater than threefold, in non-permissive LCLs.
Five of the ten genes signiﬁcantly overexpressed in permissive
LCLs (Table 2, right column) are associated with ER stress or the
unfolded protein response (UPR). The UPR is a sequence of events
induced by accumulation of unfolded proteins in the ER, leading to
rapid breakdown of these proteins followed by enhanced new protein
synthesis and sometimes autophagy. UPR genes suggested by the
microarray results and then measured using RT-PCR included ARMET,
ATF6, CALR, DDIT4, DNAJB11, FKBP11, HSP90B1, HSPA8, PPIB, and
SDF2L1, encoding ER proteins, and the downstream transcription
factors ATF4 and XBP1. Eight of the ten ER genes were overexpressed
in permissive LCLs (Fig. 8A); ATF4 and XBP1 expression did not differ
between the two groups of LCLs, but correlated positively and linearly
with LMP1 expression (p=0.005 for ATF4, p=0.034 for XBP1).
One branch of the UPR leads to upregulation of XBP-1 mRNA, and
another leads to splicing of XBP-1 mRNA to produce its active XBP-1sisoform. Although lytic permissivity did not correlate with XBP-1
expression, we considered that it might correlate with its splicing. To
look for such a relationship, we determined the relative quantities of
spliced and unspliced transcripts by SYBR Green PCR followed by
dissociation curve analysis to distinguish the two isoforms. No
relationship was detected (Fig. 8D), suggesting that EBV reactivation
does not induce the UPR despite being found at higher levels in cell
lines with more propensity for UPR activity.
Discussion
Lymphoblastoid cell lines are useful models for the processes of
EBV Latency III, for EBV-infected B cells in disease (e.g. PTLD), for
living genetic repositories and as HLA-matched immunological
targets. By proﬁling a large panel of LCLs we have investigated the
extent to which latently infected B cells vary in permissivity for EBV
reactivation, a property which inﬂuences long-term viral persistence
as well as transmission by the production of free virus in the tonsils.
Spontaneous reactivation in the cultured LCLs was characterized by
viral DNA replication and the production of early and late lytic
proteins. Depending on the cell line, between 0.1% and 8% of cells in
62 M.L. Davies et al. / Virology 400 (2010) 53–67an LCL were producing the lytic switch protein ZEBRA and, of these
producers, about 20% made late structural proteins. In general, LCLs
could be classiﬁed into two groups. One group was composed of
“permissive” LCLs with high and ﬂuctuating amounts of EBV DNA/
cell (N200 copies/cell), lower levels of latent gene expression, and
high frequency of lytic gene positive cells. The other group consisted
of “non-permissive” LCLs that had low amounts of EBV DNA/cell
(10–200 copies/cell), variable levels of latent gene expression, and a
low frequency of lytic gene positivity. Statistical analysis suggested a
weak negative relationship between the abundance of latent viral
genes in an LCL and its permissivity for lytic reactivation.
The only latent gene for which there was a positive correlation was
LMP2A. Although LMP2A may maintain latency by blocking cross-
linked BCR from inducing lytic reactivation (Fukuda and Longnecker,
2005), there is evidence that LMP2A downregulates Pax-5 and EBF-1
expression, enhances differentiation into plasma cells, and induces Z
promoter activity, all factors associated with increased lytic reactiva-
tion (Portis and Longnecker, 2003; Schaadt et al., 2005; Swanson-
Mungerson et al., 2006). For every latent transcript, except LMP2A,
the mean expression level in permissive LCLs was lower than that in
non-permissive LCLs, although this difference was only statistically
signiﬁcant for the EBNA3 genes. These ﬁndings do not support models
in which EBV latency proteins restrict the induction of the lytic cycle
in proliferating cells. Indeed, of all the latent genes measured, LMP1
had the highest level of expression and by far the least difference in
expression between permissive and non-permissive LCLs, making it
implausible that variations in LMP1 expression account for permis-
sivity towards EBV reactivation. All LCLs were immortalized with the
same strain of EBV (B95-8), which minimizes the possibility that
permissivity related to virus strain variation. Lytic permissivity did not
correlate with the amount of time spent in culture, and culturing LCLs
with an inhibitor of lytic replication did not alter their permissivity. All
of the above analyses suggest that permissivity for spontaneous lytic
reactivation was not inﬂuenced by viral factors, with the possible
exception of LMP2A.Fig. 8. Differential expression between permissive and non-permissive LCLs determined by
expression of 90 cellular mRNAs, using RT-PCR and normalizing to both B2M and GAPDH. (
genes. (C) Relative expression of transcription factors that maintain B cell lineage. (D) Perm
by SYBR Green RT-PCR followed by amelt curve used to detect the relative amounts of XBP-1
permissive (open) groups, and asterisks indicate p≤0.05 from Student's t test.It was clear from longitudinal analyses of LCLs that the difference
in lytic permissivity was a stable property of an LCL. It was
reasonable to suspect that lytic permissivity could be due to
properties that were intrinsic to the founder B cell. Gross phenotypic
properties such as doubling time, clumping, or the morphology and
size of cells were not associated with lytic permissivity. Cellular
factors, whose expression is expected to be a stable characteristic of
a cell line, were investigated. Initially we analyzed expression of a
range of B cell surface markers that deﬁne ontological status and
observed that only in permissive LCLs did more than 30% of the cells
stain positive for B220, a marker for naive primary B cells. Although
this was intriguing, there was not an accompanying low level of
CD27 and IgD on permissive LCLs, which would be expected for a
naive cell lineage. We also investigated whether permissive LCLs
contained a higher percentage of cells with the CD27hi CD38hi
phenotype characteristic of in vitro plasmacytoid differentiation, but
this was not the case.
If intrinsic cellular factor(s) were responsible, the variation would
need to be subtle. In addition to unpredictable epigenetic effects on
gene expression in transformed cell lines, genetic polymorphisms can
lead to varying expression levels of genes in otherwise comparable
cells from different individuals. Genetic analyses have connected
single nucleotide polymorphisms (SNPs) in the IFNG, TGFB1, IL10 and
IL1A genes with EBV-associated PTLD-like disease (Babel et al., 2007;
Dierksheide et al., 2005; Hatta et al., 2007). EBV reactivation after
transplantation has been correlated with an IFNG genotype that
produces low basal levels of IFN-γ (Bogunia-Kubik et al., 2005). SNPs
that lead to a high basal level of IL-10 expression (da Silva et al., 2007),
and SNPs in HLA-A (Niens et al., 2006), have been associated with
susceptibility to EBV+ HD. To learnmore about the patterns of cellular
gene expression that may inﬂuence LCLs' permissivity for lytic
reactivation, we ﬁrst conducted an RNA microarray.
The results from gene set analysis of our microarray suggested that
genes upregulated by IFN-γ and IFN-αwere overexpressed as a whole
in non-permissive LCLs. IFNG itself is listed in Supplementary Table 7RT-PCR. Permissive LCLs (n=7) and non-permissive LCLs (n=7) were measured for
A) Relative expression of UPR/chaperone genes. (B) Relative expression of plasma cell
issive LCLs (n=11) and non-permissive LCLs (n=9) were measured for XBP-1 splicing
s and XBP-1umRNA. Horizontal bars show themeans of the permissive (ﬁlled) and non-
63M.L. Davies et al. / Virology 400 (2010) 53–67among the genes overexpressed in non-permissive LCLs, along with
other cytokine genes including IL15, GDF15 (MIC-1), TNFSF4 (OX40L),
TNFSF13B (BAFF), two MIP-1α chemokines (CCL3, CCL3L3) and one
MIP-1β chemokine (CCL4L2). In permissive LCLs, IL4 (an anti-
inﬂammatory cytokine known to counteract IFN-γ) was over-
expressed along with pro-inﬂammatory cytokines IL1A, MIF, PRL
(prolactin), and three other cytokines, CKLF, CMTM3, and CMTM7.
Most of these genes were low in absolute amount of transcripts
produced and the results were less robust than for other genes
discussed below. The overexpression of pro-inﬂammatory cytokines
in permissive LCLs may suggest a role in creating a milieu that lowers
signaling thresholds for activation of the lytic Z or R promoters.
Also overexpressed in non-permissive LCLs were potential target
genes of oncogenic microRNAs 155 and 221/222. miR-155′s targets
include PU.1, CEBP/β, BACH1, SOCS1, AID, and SHIP1, and it is
upregulated by TGF-β signaling (Kong et al., 2008; Lu et al., 2009;
O'Connell et al., 2009; Yin et al., 2008). This microRNA has been linked
to Latency III, Hodgkin's disease, PTLD, and DLBCL and AML leukemias,
and is not associated with Latency I lymphomas (Kluiver et al., 2006;
Teng and Papavasiliou, 2009). miR-155 orthologs are encoded by
oncogenic herpesviruses HHV-8 and MDV-1, and miR-155 is induced
by EBV LMP1 (Gatto et al., 2008; Zhao et al., 2009). miR-221/222
enhances the progression of several malignancies by inhibiting the
cell cycle regulator p27Kip1 and is upregulated byMDV-1 in lymphoma
cells (Lambeth et al., 2009; le Sage et al., 2007).
Plasma cell-associated genes were expressed differentially in the
microarray. Signiﬁcantly, of the curated gene sets gleaned from earlier
publications, the one most overexpressed in permissive LCLs was a
group of 80 genes overexpressed in plasma cell and plasmablast
subsets and underexpressed in peripheral blood and tonsillar B cells
(Tarte et al., 2003). A few of these genes were individually over-
expressed in permissive LCLs, including HYOU1, TNFRSF17, PRG1,
DDOST, PPIB, HSPA5, ARMET, and HSP90B1, the last ﬁve of which have
been associated with the unfolded protein response. Also, when
examining sets of genes which shared a known promoter motif, we
found that among the few overexpressed in permissive LCLs were the
sets of genes whose promoters contained recognition sites for XBP-1,
ATF-6, and HTF-1. HTF-1 is a rat homologue of XBP-1, and ATF-6
induces the expression of XBP-1 (Yoshida et al., 2001).
These ﬁndings suggest that non-permissive LCLs have gene
expression proﬁles that support stable proliferation rather than
terminal differentiation into PC. In this regard, non-permissive LCLs
overexpressed a set of genes downregulated by the tumor suppressor
gene p21 in a p53-dependent fashion, and permissive LCLs over-
expressed a set of genes upregulated by p53. The gene for p21
(CDKN1A) was seen in later experiments to be overexpressed in non-
permissive LCLs, though this was not statistically signiﬁcant (1.3-fold
enrichment; p=0.108). With regard to PC differentiation, non-
permissive LCLs overexpressed a gene set associated with a
“proliferation” subgroup of multiple myeloma (MM) that predicts a
bad prognosis compared with other MM cases (Zhan et al., 2006), and
gene sets upregulated in MM cells activated by the oncogene N-ras or
exposed to the pro-proliferative cytokine IL-6. Also overexpressed in
non-permissive LCLs was a set of genes downregulated in primary
effusion lymphoma, identiﬁed in a study that concluded that PEL may
be derived from plasmablasts (Klein et al., 2003).
When we compared LCLs grown with and without acyclovir
there were negligible differences in gene expression, suggesting that
neither the drug treatment nor late lytic viral events inﬂuenced the
results of the microarray. Genes identiﬁed by this microarray study
as potentially involved in lytic permissivity, and other genes of
interest, were selected for further study using RT-PCR. Many gene
expression studies have been done on the effects of EBV infection of
B cells, but this is the ﬁrst to characterize a variety of genetically
distinct LCLs, all immortalized in the same way with the same strain
of virus.Thus far, the list of genes known to induce or repress lytic EBV
replication is short. In physiological situations, the R promoter mainly
responds to BZLF1 (Kieff and Rickinson, 2007). The Z promoter has
been extensively characterized for binding sites, including motifs
activated by XBP-1 and the BZLF1 protein it encodes (Sun and
Thorley-Lawson, 2007), and repressed by signaling from CD40 as well
as EBV LMP1 (Adler et al., 2002). We saw that CD40 expression did
correlate negatively with lytic permissivity, although LMP1 expres-
sion did not. CD40 was the most differentially expressed gene in the
RT-PCR comparison of seven permissive and seven non-permissive
LCLs (Table 2). Because CD40 emerged as signiﬁcant in this objective,
large-scale comparison, we are encouraged that functional signiﬁ-
cance might attach to other genes detected in the same study.
The unfolded protein response (UPR) is activated when B cells
become antibody-secreting cells and during some productive virus
infections, although there is no evidence that UPR activation is
induced by herpesvirus reactivation. Some herpesviruses inhibit the
UPR during productive infection to create an environment that
sustains lytic replication, or induce it as part of an immune evasion
strategy (Lee et al., 2009). EBV LMP1 induces the PERK/ATF-4
pathway of the UPR, which leads initially to further upregulation of
LMP1, and then at higher levels to LMP1 degradation by autophagy
(Lee and Sugden, 2008). This biphasic pattern probably titrates LMP1
expression to ensure an appropriate level of constitutive signaling to
sustain the proliferation of EBV-transformed cells. Expression of two
transcription factors downstream of UPR activation, ATF4 and XBP1,
correlated positively with LMP1 expression in our study, suggesting
that LCLs vary in the degree to which they undergo the LMP1/PERK/
ATF-4 feedback cycle. Importantly, this variation was not associated
with the level of lytic permissivity. We also investigated ten UPR
proteins that localize in the ER, and eight were overexpressed in
permissive LCLs, including ﬁve of the ten most signiﬁcantly over-
expressed (HSP90B1, DNAJB11, SDF2L1, CALR, ARMET). These ER
proteins did not correlate with LMP1, and did not include any of the
stress response proteins recently found to be induced by EBNA3A
(Young et al., 2008). We cannot rule out the possibility that this
association of UPR gene overexpression with lytic permissivity
actually reﬂects the induction of the UPR by EBV reactivation.
However, the same association was found in LCLs cultured with
ACV, and it is unclear whether these genes are indicative of enhanced
UPR activity, or are inherently present at higher levels enabling the
cells to have a more acute response if and when ER stress sensors are
activated. Experiments now underway suggest that UPR proteins are
expressed at a consistently high level in permissive LCLs, and are not
concentrated in the minority of cells undergoing lytic reactivation.
In general, as shown in Table 2 (a subset of the larger RT-PCR results
shown inSupplementary Tables 8 and9),more geneswere signiﬁcantly
overexpressed in non-permissive LCLs than in permissive LCLs. In our
microarray results the lists of genes overexpressed in non-permissive
LCLs also contained more transcription factors, a trend that exists for
activators, repressors, coactivators and corepressors (Supplementary
Table 7). This suggests that some EBV-transformed B cell lines repress
lytic reactivation more tightly because of a milieu of factors that
counteract the cells' tendency to experience a positive feedback loop of
BZLF1 expression and thus trip over into lytic reactivation.
Signaling from CD40 or LMP1 leads to the activation of transcrip-
tion factors that repress the Z promoter. We detected a number of
genes whose expression was greater in the non-permissive LCLs, but
none are known to be upregulated by CD40 or LMP1. One study found
that Pax-5 and EBF-1 activity were enhanced by CD40 signaling, but
CD40 did not affect the levels of these factors (Merluzzi et al., 2004).
Several genes that have been seen as upregulated by lytic replication
of EBV or other herpesviruses were nonetheless associated with the
non-permissive phenotype in our LCLs, further suggesting that our
ﬁndings did not reﬂect downstream effects of EBV reactivation. For
example, EGR1/Zif-268 is directly induced by BZLF1 and directly
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upregulated by lytic replication of EBV, HHV-8, CMV, and HSV
(Khodarev et al., 1999; Naranatt et al., 2004; Yuan et al., 2006; Zhu
et al., 1998). However, we found both these factors among the genes
overexpressed in LCLs with less lytic permissivity. Many genes we
investigated by RT-PCR had been detected in earlier studies to be
upregulated or downregulated by EBV Latency III proteins, but were
not regulated in either direction in our study (e.g. JUND, EBI3, TIMP1,
TNFRSF14). This might be expected, since every LCL was producing the
full complement of Latency III proteins, and EBNA2 and LMP1
expression did not correlate with permissivity.
Most signiﬁcant was the group of transcription factors which
maintain B cell lineage from the pre-B cell phase to the point of
terminal differentiation into PCs. During the transition to a plasma-
blastic phenotype this network of factors, including EBF-1, Pax-5, and
E2A, gives way to a network of factors that had been repressed, led by
Blimp-1, which suppresses Pax-5 and thus removes restraints on XBP-
1 production (Nutt and Kee, 2007). Although lytically permissive LCLs
did not containmore PRDM1/Blimp-1, IRF4, unspliced XBP1, or spliced
XBP1 mRNA, the major members of the opposite network were all
overexpressed in non-permissive LCLs. EBF1, PAX5, and TCF3/E2A
were among the 18 genes with signiﬁcantly enhanced (pb0.05)
expression in non-permissive LCLs, and EBF1 had the most signiﬁcant
p-value of any gene with a N3-fold difference between the means of
the two populations. In addition, ETS1, which encodes a transcription
factor that upregulates EBF-1 and Pax-5 by repressing Blimp-1 activity
(John et al., 2008), was one of eight overexpressed genes with pb0.01
in this comparison.
Taking our results as a whole, we suggest that each line of Latency
III-transformed B cells has a characteristic frequency of EBV lytic
reactivation which is attributable to the intrinsic levels of a few key
cellular proteins that inﬂuence gene expression. We further suggest
that in addition to the known effects of XBP-1 on BZLF1 expression,
the XBP-1-containing pathway may be relevant in a different way.
When LCLs produce high amounts of factor(s) that repress the activity
of XBP-1 and Blimp-1, they also repress the level of spontaneous lytic
reactivation. From this study the best single candidate for such a
controlling factor is EBF-1.
Materials and methods
Establishment of LCLs and cell culture
Lymphoblastoid cell lines were established by suspending PBMCs
in RPMI-1640 including 20% FBS and tacrolimus, to which was added
supernatant from the B95-8 virus-producing cell line. After 10–15
days of incubation the viral supernatant was removed and immortal-
ized cells weremaintained for at least 4 weeks before being used; they
were then grown in RPMI-1640 including 10% FBS, 2 mM L-glutamine,
100 units/ml penicillin and 100 μg/ml streptomycin. For inhibiting
lytic viral replication, acyclovir was added to the media at a
concentration of 22.5 μg/ml. A total of 62 LCLs from 62 different
donors were studied. These lines had been established for two
separate immunological studies. The collection of pediatric LCLs was
established during a PTLD study, and the adult LCLs were established
during an HIV-related study. After determining the average genome
copy number/cell, cell lines with N200 copies/cell were classiﬁed as
permissive for spontaneous lytic virus induction.
Cell lysis and PCR
For DNA measurement, cell pellets were lysed in 10 mM Tris (pH
7.6) containing 50 mM KCl, 2.5 mM MgCl2, 1% Tween 20, and
0.1 mg/ml proteinase K. For measuring the number of EBV genomes,
we detected a sequence in the BLLF1 gene encoding viral gp350
(forward primer 5′-GTATCCACCGCGGATGTCA-3′; reverse primer 5′-GGCCTTACTTTCTGTGCCGTT-3′; probe 5′FAM-TGGACTTGGTGT-
CACCGGTGATGC-TAMRA-3′). For normalizing to the amount of
cellular DNA, we detected a sequence in human GAPDH (Xu et al.,
2006). Lysates of the EBV-negative DG75 B cell line were used as
standards for GAPDH DNA, while lysates of the Namalwa cell line,
each of which contains two integrated copies of the EBV genome,
were used as standards for EBV DNA.
For RNA measurement, RNA was extracted from cell pellets using a
VersaGene cell kit (Gentra); RNAwas thenDNAse-treatedusing a Zymo
Research kit, and transcribed into cDNA using MultiScribe reverse
transcriptase (ABI). For each target transcript, the standards used were
puriﬁedPCR product containing a knownnumber of copies of the target
sequence, and normalized to cell number by measuring β2-micro-
globulin cDNA, using a predesigned primer set (Applied Biosystems).
PCR targets
EBV mRNA targets included the latent genes EBNA1, EBNA2,
EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2A, and LMP2B, and the lytic
genes ZEBRA and BMLF1. Also quantiﬁed were the number of
transcripts from the C, W, and Q promoters. Qp is a latent promoter,
but a measurement of its transcripts also detects transcripts from the
lytic F promoter. For both Cp and Wp, two alternative splices were
measured—a nonproductive splice that encodes EBNA1, -2, -3A, -3B, or
-3C; and a productive splice that encodes EBNA-LP as well as one of the
other EBNA proteins. The amount of EBNA-LP mRNA can be measured
as the sum of the Cp and Wp productive splices.
All EBV transcripts except BMLF1 were quantiﬁed with primers
crossing an mRNA splice site, detecting cDNA but not genomic DNA.
Primer sequences are supplied in Supplementary Table 1. All PCR was
quantitative real-time PCR performed on an ABI 7500 instrument.
Flow cytometry
Proliferating cells were washed in cold PBS, and chilled and stained
in FACS buffer (HBSS including 2.0% BSA and 0.1% sodium azide). The
following mouse α-human monoclonal antibodies were used: PE-α-
IgG (clone G18-145, BD); PE-α-CD138 (clone M115, BD); PE-α-BR3
(clone 11C1, BioLegend); PE/Cy5.5-α-CD19 (clone SJ25-C1, Caltag);
PE/Cy7-α-HLA-DR (clone L243, BioLegend); APC-α-IgM (clone MHM-
88, BioLegend); Alexa647-α-CD23 (clone D3.6, BioLegend); Alexa647-
α-CD30 (clone MEM-268, BioLegend); APC/Cy7-α-CD20 (clone 2H7,
BioLegend); APC/Alexa750-α-CD27 (clone CLB-27/1, Caltag); Paciﬁc
Blue-α-HLA-A,B,C (clone W6/32, BioLegend); Paciﬁc Blue-α-CD45
(clone HI30, BioLegend); Paciﬁc Blue-α-CD69 (clone FN50, Bio-
Legend); biotin-α-IgD (clone IA6-2, BD); biotin-α-CD38 (clone AT13/
5, AbD Serotec); and biotin-α-CD40 (clone LOB7/6, AbD Serotec). We
also used PE/Cy7-conjugated rat α-mouse B220 (BD), and FITC-
conjugated polyclonal goat antibodies (Biosource) speciﬁc for human
IgA and for all human Igs (pan-Ig). Antibodies against viral proteins
includedmouseα-ZEBRA (clone BZ.1, Santa Cruz), andmouseα-gp110
(clone 5B2, Abcam), which were labeled with Alexa Fluor-conjugated
Zenon goat F(ab)2 fragments (Molecular Probes). Cell surface staining
was done with live cells, with streptavidin-Paciﬁc Orange (Molecular
Probes) used to label biotinylated antibodies; in intracellular staining
for viral genes, 1% formaldehyde and 0.1% Triton X-100 was used to ﬁx
and permeabilize cells. The samples were measured in a BD FACSAria,
and data were analyzed using FACSDiva and FlowJo software.
Gene expression microarrays
RNA was isolated using the TRIzol process (Invitrogen), and
technicians at the University of Pittsburgh Genomics and Proteomics
Core Laboratories (GPCL) transcribed it into cDNA, which was hybri-
dized to Illumina HumanRef-8 v2 BeadChip arrays. Software used to
analyze the data included caGEDA (http://bioinformatics2.pitt.edu/
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(http://david.abcc.ncifcrf.gov/) and Ingenuity Pathways Analysis
(Ingenuity) to get information about gene ontologies, pathways and
biological roles of each gene of interest; and GSEA (http://www.broad.
mit.edu/gsea/) to get information about entire sets of genes, rather
than individual genes, that were upregulated in each sample popula-
tion. GSEA analyses were done with the following settings: 1000
permutations; genes identiﬁed by HUGO gene symbol with collapse
dataset set to false; weighted enrichment score normalized by gene set
size; gene sets from GSEA databases c2.all.v2.5.symbols.gmt (curated)
and c3.all.v2.5.symbols.gmt (motif); andgene sets ofb15orN500genes
ﬁltered out. The J5 score is a measure of the scale of difference of the
sample group means for a given gene relative to the average difference
of all the genes on the array (Patel and Lyons-Weiler, 2004).
RT-PCR arrays
RNAwas isolated using the TRIzol process and reverse-transcribed
using the High-Capacity kit (ABI); cDNA was mixed with TaqMan
Gene Expression Master Mix and applied to custom-made 384-well
plates (Low-Density Arrays, ABI) containing primers for 92 genes of
interest and 4 endogenous controls. Seven permissive and seven non-
permissive LCLs were measured. For four LCLs, RNA was taken on two
dates and measurements were averaged together; the rest were
measured on one date. Five were assessed both with and without
acyclovir, to reafﬁrm that viral replication has a negligible inﬂuence
on the cellular gene expression across the whole cell line; the rest
were only measured without acyclovir. PCR was performed on an ABI
7900HT at the GPCL, and data were analyzed using SDS2.1 software
(ABI), Microsoft Excel, and Minitab 15. Results from RT-PCR arrays
were quantiﬁed using the 2−ΔΔCt method (for each sample, taking the
difference between each experimental gene's cycle of detection (Ct)
and that of an endogenous control gene, and then comparing this
difference to the difference in a reference sample).
Relative quantitation of XBP-1u and XBP-1s mRNAs
XBP-1 cDNAs were generated by random hexamer RT, and
ampliﬁed using the ABI 7300 Real-time PCR System, SYBR green
qPCR master mix reagent (Fermentas), and the following primers:
XBP-1 forward: 5′-GTTGAGAACCAGGAGTTAAG-3′; XBP-1 reverse 5′-
GAGAAAGGGAGGCTGGTAAG-3′ to generate 357nt (XBP-1u) and
331nt (XBP-1s) amplicons. Amplifaction conditions were 95 °C for
20 s, followed by 21 cycles of 95 °C for 5 s and 60 °C for 30 s. To
quantitate relative XBP-1 splicing, dissociation curve analysis was
performed post-run, according to the manufacturer's instructions.
Relative XBP-1 splicing was calculated by comparing peak heights
from the unspliced (Tm 85.7 degree) and spliced (Tm 82.7 degree)
peaks, and measured as the ratio of XBP1s / (XBP1s + XBP1u).
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